↑ Grab this Headline Animator

Basic Platform Report CRC Therapeutics

Research and Markets (http://www.researchandmarkets.com/reports/c24651) has announced the addition of Basic Platform Report: CRC Therapeutics to their offering



"Basic Platform Report: CRC Therapeutics" provides a complete and systematic description of the past and present efforts in the development of colorectal cancer (CRC) therapeutics.



We have identified structured and defined information necessary to analyze the most drugs currently under development. More than 200 R&D projects have been identified. Several thousands of records from a multitude of sources build the structure and content of this product. The report is divided in 6 sections each section structured to enable the study of a specific topic (see below). "Basic Platform Report: CRC Therapeutics " is a unique gathering of information found no were else. The information structure will provide an easy reading format to track B2B collaborations and industry academic relationships as well as identify candidates receiving Fast Track Designations and Orphan Drug Status.



This + 1000 pages basic platform report is arranged into several major sections to optimize the usability of the report. Below you find general descriptions of the advantage of using this report.



Section I: Investigators



This section will enable our customers to rapidly study and identify which investigators are active in CRC targeting R&D. It will as well assist in studying and build up a complete picture of research activities among the different investigators who are active in this field.



Section II: Drug candidates



This section will assist in studying R&D activities and progress for the different drugs included. It will give a historical review of the progress of each drug and structure all collaborative partners involved in R&D for each drug candidate. Section II gives you a possibility to study activities and efforts for each drug in relation to different cancer indications.



Section III: Developmental stage



This section enables you to structure and study the level and progress that each drug candidate has reached. The time frame for a drug to progress from the different developmental phases (pre-clinical up to approved) reflects difficulties and commitment among the investigators.



Section IV: Therapeutic types



This section enables you to track down competition among the different therapeutic types under development. Most types of therapeutic strategies have been defined and labeled as: Small molecular drugs, biological drugs, monoclonal antibodies, anti-sense, gene therapy, cell therapy, or vaccines etc.



Section V: Mechanism of action & Targets



In this section the author provides an extensive architecture over mechanisms and targets for the different drug candidates. It is divided in two categories, mechanisms and targets. Mechanisms included in this report are: Growth factor receptors, proliferation signaling, cell cycling, apoptosis, angiogenesis, and the immune system. etc. Some of the identified targets are: Caspase 3, Colony stimulating factor 2, COX, Cyclin-dependent kinase inhibitor 1A, DNA (cytosine-5-)-methyltransferase 1, Epidermal growth factor receptor, Eukaryotic translation elongation factor 1 alpha 1 etc.



Section VI: Drug effects



In this section the author organizes candidate drugs after their therapeutic effect. Drug effects used: Anti-angiogenesis, Anti-mitotics, Apoptosis, Cytotoxic, Growth inhibitors, Hormonal therapies, Immunotherapy, Radiosensitizers, Vascular targeting agents etc.







Example of candidate drugs



The complete number of candidate drugs in R&D for CRC are more than 200 and we have listed some of them below:



AMG 706, batabulin, becatecarin, bevacizumab, canvaxin, DRF 1042, EP 2101, folic acid analogue, ADVENTRX, HSPPC 96, HyCAMP, IB-MECA, Maxy 1200, MS 275, NB 1011, NV 1020, oblimersen, panitumumab, patupilone, PD 0325901, picoplatin, SGN 15, tetrathiomolybdate, triacetyluridine, troVax, vatalanib



Companies Mentioned



Acera Biosciences, ADVENTRX, Agensys, Amgen, AnorMED, Antigenics, Attenuon, AVI BioPharma, Can-Fite, Cell Therapeutics, Corixa, Cosmo Bioscience, Dr Reddy's, Elan, Epimmune, GemVax, Genencor, Genentech, GenVec, GlaxoSmithKline, Hoffmann La Roche, Igeneon, Immunomedics, Inex, J&J, MediGene, MedImmune, MediPharm, Millennium, Novartis, Novozymes, Onyvax, OXiGENE, Pfizer, Phytopharm, Prolexys, Scancell, Schering AG, Seattle Genetics, Serono, Structural GenomiX, Supergen, Taiho, Threshold, Titan Pharmaceuticals, Transgene, Wyeth, Xenova









For more information visit http://www.researchandmarkets.com/reports/c24651



Laura Wood

Senior Manager

Research and Markets

Fax: +353 1 4100 980

↑ Grab this Headline Animator

---

This article has been robotically scanned and tagged by Prnewsnow with the following search tags. No human manipulation of these tags take place.
| Webcom | Websource Cpq | low voltage products |

---

4944 readers online...

, Local News